...
首页> 外文期刊>Internal medicine journal >Direct-to-consumer personal genome testing: ethical and regulatory issues that arise from wanting to 'know' your DNA.
【24h】

Direct-to-consumer personal genome testing: ethical and regulatory issues that arise from wanting to 'know' your DNA.

机译:面向消费者的个人基因组测试:想要“了解”您的DNA会产生道德和监管问题。

获取原文
获取原文并翻译 | 示例
           

摘要

Direct-to-consumer personal genome testing (DTC-PGT) screens a customer's genome for the presence of single nucleotide polymorphisms that are reported to be associated with various diseases, disease risk factors and personal characteristics. The range of health risks covered by personal genome testing (PGT) includes cancer, heart disease, obesity, diabetes mellitus and osteoporosis. PGT also detects a range of other characteristics, such as alcohol 'flush reaction', eye colour, ear wax type and bitter taste perception. Information about ancestry and family history is also available. Although DTC-PGT is still a relatively new enterprise, the technology has the potential for rapid expansion as it becomes more accessible to consumers who wish to obtain information about their genetic profile. This review provides an overview of the broader ethical and regulatory issues raised by personal genome tests that are marketed directly to the public, and that purport to provide information about health risks. We discuss the emergence of DTC-PGT in Australia, and the possible regulatory responses that may be taken to manage it.
机译:直接面向消费者的个人基因组测试(DTC-PGT)对客户的基因组进行筛查,以检查是否存在单核苷酸多态性,据报道该多态性与各种疾病,疾病风险因素和个人特征有关。个人基因组测试(PGT)涵盖的健康风险范围包括癌症,心脏病,肥胖症,糖尿病和骨质疏松症。 PGT还检测一系列其他特征,例如酒精“潮红反应”,眼睛颜色,耳垢和苦味觉。也提供有关血统和家族史的信息。尽管DTC-PGT仍然是一个相对较新的企业,但该技术具有迅速扩展的潜力,因为它希望为希望获取有关其遗传特征的信息的消费者提供更多的机会。这篇综述概述了直接向公众销售的个人基因组测试所引发的更广泛的道德和监管问题,这些问题旨在提供有关健康风险的信息。我们讨论了DTC-PGT在澳大利亚的出现,以及可能采取的监管对策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号